Two molecules, five brand names, and a great deal of confident internet opinion. Semaglutide and tirzepatide are the medications most people in this category are actually taking, and the comparison between them is almost always framed as a single question: which one is better.
That turns out to be the least useful question on offer, and we will get to why. The differences that change what you do week to week are much more concrete, and they begin with a piece of confusion that causes real errors in real logs.
Which brand is which molecule
Before anything else, the map.
- Semaglutide: Ozempic (weekly injection), Wegovy (weekly injection), Rybelsus (daily tablet).
- Tirzepatide: Mounjaro (weekly injection), Zepbound (weekly injection).
This matters more than it looks. Brand names travel through conversation far more easily than molecule names do, so the five brands get discussed as though they were five different drugs. They are two, running on two ladders with two sets of rules.
The sharpest version of the problem is the dose numbers, because the milligram scales do not correspond at all. Wegovy tops out at 2.4 mg. Mounjaro and Zepbound start at 2.5 mg and climb to 15 mg. Two numbers a tenth of a milligram apart, one of them the end of a ladder and the other the first rung of a different one. Read a dose without knowing which molecule it belongs to and you can be off by an entire treatment course while feeling perfectly well informed.
One receptor or two
The mechanism difference is real and can be put in two sentences. Semaglutide engages the GLP-1 receptor. Tirzepatide engages two receptors, GIP as well as GLP-1.
Why a second receptor was worth adding, and why GIP spent years looking like a dead end before anyone did, is a genuinely good story and it is not this article's. Our explainer on GIP and glucagon covers it properly. For present purposes the translation is short: this is a different pharmacology, not an upgraded edition of the same one, which is part of why two people can have quite different experiences of the two medications, and why one person can too.
The differences that change your week
Here is the practical side by side, drawn from the published labels.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Brands | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Receptors | GLP-1 | GIP and GLP-1 |
| Half-life | About 1 week | About 5 days |
| Time to steady state | About a month | About a month |
| Weekly ladder (mg) | Ozempic 0.25, 0.5, 1.0, 2.0; Wegovy 0.25, 0.5, 1.0, 1.7, 2.4 | Mounjaro and Zepbound 2.5, 5, 7.5, 10, 12.5, 15 |
| Missed dose | Ozempic within 5 days; Wegovy as soon as possible if the next dose is more than 2 days away, otherwise skip | Within 4 days (96 hours) |
| Minimum gap when shifting shot day | 48 hours | 72 hours |
| Oral option | Rybelsus, daily tablet | None |
Three things in that table are worth a sentence each.
The half-life difference is small in words and visible in the rules. Five days against a week is why tirzepatide's grace window is 4 days where Ozempic's is 5, and why doses have to stay 72 hours apart instead of 48. Our tirzepatide half-life article walks the level math behind those numbers; the missed dose guide has the exact label wording for every medication in the family. One rule is shared by every label in the class: never take a double dose to make up for a missed one.
Both take about a month to level off. Whichever you are on, the first month is a climb rather than a verdict, and each ladder step restarts a smaller version of it, which we cover in steady state in plain English.
The ladders are different lengths. Four or five steps against six, each typically held for around four weeks. A longer ladder means a longer ramp before anyone can see what a maintenance dose does, which is worth knowing before you start counting weeks.
For a log, the practical upshot is simple: the ladder step is as important as the dose. Recording 5 mg means very little on its own. Recording 5 mg as step two of six, in week three of that step, is the entry your prescriber can actually use.
It is just as useful to know what does not differ, because a surprising amount of the routine is identical. Both are weekly subcutaneous injections using the same approved sites, abdomen, front of the thighs and back of the upper arms, with the same reasons to rotate. Both are stored refrigerated until in use, with room-temperature limits that differ by product and are printed on the label. Both produce their most commonly reported effects, nausea in particular, around dose increases rather than at random. And both reward the same five-line weekly entry: when, how much, which step, which site, how it went.
GLP 1 Tracker AppFree on the App Store. Both ladders built in, with week counts, an educational level curve and a side effect diary.
Get the app
The one head-to-head trial, read carefully
An article with this title cannot honestly skip the direct comparison, because one exists.
SURMOUNT-5 was a 72-week open-label randomized trial of 751 adults with obesity and without type 2 diabetes. It compared maximum tolerated doses of tirzepatide (10 or 15 mg) against maximum tolerated doses of semaglutide (1.7 or 2.4 mg). Mean weight reduction was 20.2 percent with tirzepatide and 13.7 percent with semaglutide. It was published in the New England Journal of Medicine.
Now the part that matters more than those two numbers.
- They are group averages, from one trial, in one population. A mean sits in the middle of a wide spread of individual results. It describes what happened to a group; it does not forecast what will happen to a person.
- That population was specific. Adults with obesity and without type 2 diabetes. If that does not describe you, the trial does not describe your situation either, and no amount of reading around the edges changes that.
- Tolerability is not inside the headline number. Response varies widely between people, and so do side effects. A medication someone cannot stay on is not the better medication for them, whatever a group average says.
- The decision belongs to a prescriber, with you in the room. One trial is a piece of evidence, not an instruction.
We are deliberately not writing the flat one-line verdict you might be expecting here, and we would be careful with any article that does. A trial result is a finding about a study population. It is not a ranking that transfers cleanly onto you.
What actually decides it in practice
Ask what settles this choice for real people and the trial is rarely the first thing that comes up. Four other things usually get there first.
- Tolerability. The medication you can stay on beats the one you cannot, every time. This is also the thing your own record answers better than your memory does, which is the argument our guide to tracking side effects makes at length.
- Your other conditions and medications. Type 2 diabetes, previous reactions, everything else on your list. This is where the individualized part of the decision genuinely lives.
- Insurance coverage. Which of these is covered, and on what terms, decides more prescriptions than any trial does. Our guide to prior authorization and the data behind it covers what tends to be asked for.
- Availability. Supply in this category has moved around more than once, and a medication you cannot fill is not an option this month. We wrote about tracking through a supply gap separately.
None of those can be settled by a comparison article, and all of them are informed by a record of how your current medication has actually gone. If a switch does end up on the table, that transition has a logic of its own, because the old medication's tail overlaps the new one's rise and the ladder usually starts again from the bottom; our guide to switching GLP-1 medications, linked below, covers what to track through it.
The takeaway
Semaglutide and tirzepatide are two molecules across five brands: one engaging a single receptor on a one-week clock, the other engaging two receptors on a five-day clock. That produces different ladders, different grace windows and different spacing rules, and those are the differences that change what you write down each week and what your prescriber can do with it.
The one direct trial reported a larger mean weight reduction with tirzepatide over 72 weeks in adults with obesity and without type 2 diabetes. That is a real result, and a narrow one. The better medication is still, stubbornly, the one that fits your body, your other conditions, your coverage and your prescriber's judgment. The only way to learn how a medication fits you is to take it as prescribed and keep an honest record of what happens next.
Either molecule, one logOzempic, Wegovy, Mounjaro and Zepbound ladders included. No account, nothing leaves your phone.
Download
Frequently asked questions
What is the difference between semaglutide and tirzepatide?
They are two different molecules. Semaglutide engages the GLP-1 receptor and has a half-life of about one week. Tirzepatide engages two receptors, GIP as well as GLP-1, and has a half-life of about five days. Both are weekly injections that reach a stable level after roughly a month, but they climb different dose ladders and carry different missed-dose windows, so a log has to know which one you are on.
Which brands contain semaglutide and which contain tirzepatide?
Semaglutide is the molecule in Ozempic and Wegovy, both weekly injections, and in Rybelsus, a daily tablet. Tirzepatide is the molecule in Mounjaro and Zepbound, both weekly injections. Five brand names, two molecules. Mixing them up is the most common source of tracking errors, because the dose numbers on the two ladders look similar and mean completely different things.
Is tirzepatide more effective than semaglutide?
One trial compared them directly. SURMOUNT-5, a 72-week open-label randomized trial of 751 adults with obesity and without type 2 diabetes, compared maximum tolerated doses of each and reported a mean weight reduction of 20.2 percent with tirzepatide and 13.7 percent with semaglutide. Those are group averages in one specific population, not a prediction for any individual, and a medication someone cannot tolerate is not the better one for them. The choice belongs with a prescriber.
Do semaglutide and tirzepatide have the same missed-dose window?
No, and the difference tracks their half-lives. Per the labels, a missed Ozempic dose can be taken within 5 days; Wegovy says take it as soon as possible if the next scheduled dose is more than 2 days away, and skip it otherwise; Mounjaro and Zepbound allow 4 days, or 96 hours. Doses must also stay at least 48 hours apart for semaglutide and 72 hours for tirzepatide. Never take a double dose.
Does 15 mg of tirzepatide mean more medication than 2.4 mg of semaglutide?
The numbers are not comparable. Each molecule has its own dose range, so milligrams on one ladder say nothing about milligrams on the other. Wegovy tops out at 2.4 mg, while 2.5 mg is only the starting step for Mounjaro and Zepbound, which climb to 15 mg. Nearly identical numbers sitting at opposite ends of their ladders. Always read a dose against the ladder it belongs to.